#1Фафот 0000 m Bo 000000 000000 000000 tt 0000000 19898896 S DOC HTP 55 M 0 A. 600 000 MAGNIFICENT MP THE POWER OF TRUST Government of Madhya Pradesh PHARMACEUTICAL#2A HEALTHY GLOBAL SCENARIO GLOBAL PHARMACEUTICAL MARKET SIZE IS EXPECTED TO REACH US$1.6 TRILLION BY 2020 INDUSTRY CLASSIFICATION BY THERAPY AREA (IN US$ BILLION) 250 233 12.60% 14% 200 12% 10% 150 8% 6.80% 104 100 6% 5.10% 5.60% 3.40% 59.5 55.7 56.7 3.30% 1% 50 46.1 44.6 42.4 39.9 2.60% 2.80% 1.70% 27.7 381 27.2 32.3 1.60% 13.7 12.9 30.3 21.6 26.9 23 24.4 2% 0 Sources: http://info.evaluategroup.com/rs/607-YGS-364/images/WP2018.pdf 2017 REVENUE 2024 E REVENUE % MARKET SHARE 2017 INDUSTRY CLASSIFICATION BY THERAPY AREA In 2017, the top five therapy areas accounted for 33% of the total pharmaceutical sales. Oncology has largest market share with 12.6% followed by anti-diabetics (5.6%) and anti-rheumatics (6.8%).#3GLOBAL MEDICAL TECHNOLOGY (MEDTECH) SEGMENT IS EXPECTED TO REACH US$ 454 BILLION IN 2019 INDUSTRY CLASSIFICATION BY TECHNOLOGY (IN US$ BILLION) 447 INDUSTRY CLASSIFICATION BY TECHNOLOGY In 2017, biotechnology based medicines accounted for a market share of 25.2%, which is expected to increase to 30% by 2022. 500 450 446 449 438 444 447 400 350 300 250 208 200 192 165 170 170 171 174 150-145 157 160 166 170 100 50 0 2012 2013 OTHER 2014 2015 2016 2017 UNCLASSIFIED Sources: http://info.evaluategroup.com/rs/607-YGS-364/images/WP2018.pdf BIOTECHNOLOGY CONVENTIONAL Biotech is also expected to represent 52% of the top 100 product sales by 2024 Conventional medicaments share has been stagnant SALES#4INDIAN SCENARIO Indian healthcare sector is expected to cross US$ 372 billion by 2022. Indian pharmaceutical industry accounts for about 3.6% of the global pharmaceu- tical industry by value. 60% of the world's vaccines are manu- factured in India. Every 3rd pill sold in USA is produced by an Indian generics manufacturer. The sector is expected to reach US$ 50 billion by 2025. The sector attracted more than US$ 2 billion in FDI inflows in last 3 years. MARKET SIZE OF INDIAN PHARMACEUTICAL SECTOR (US$ BILLION) CAGR: 6.41% 33 28.53 29.77 27.57 24.52 22.46 20.95 50 FY11 FY12 FY13 FY14 FY15 FY16 FY17 2025F Sources: https://www.ibef.org/industry/pharmaceutical-india.aspx Source: IBEF Research, Department of Commerce, Department of Pharmaceuticals, India Business News, BMI#5BY 2030, INDIA CAN BECOME 5TH LARGETS MARKET GLOBALLY India is among the top 20 pharmaceutical exporters. Indian drugs are exported to more than 200 countries globally with US and Europe as major export destinations. Pharmaceutical exports are expected to reach US$ 20 billion by 2020. are The major therapeutic categories of export anti-infective, anti-asthmatic and anti-hypertensive. India is the global leader in production of generic medicines, country's generic drugs account for almost 20% of global generic medicine exports (by volume). The Indian medical device market reached US$ 4.9 billion in 2019 and is expected to exceed US $7 billion by 2020. UN supported Medicines Patent Pool (MPP) has signed six sub-licences with Indian firms. This licence allows them to produce generic anti-AIDS medicine for sale in 112 developing countries. EXPORT DATA OF INDIAN PHARMACEUTICALS (US$ BILLION) 12.6 10.1 CAGR: 9.53% 14.5 14.9 16.9 168 17.3 19.1 Sources: http://planningcommission.gov.in/aboutus/committee/wrkgrp12/wg_pharma2902.pdf https://www.ibef.org/industry/pharmaceutical-india.aspx The Indian Pharmaceutical industry - the way forward, report by Indian Pharmaceutical Alliance https://www.export.gov/article?id=India-Healthcare-and-Medical-Equipment FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 Source: IBEF Research, Department of Commerce, Department of Pharmaceuticals, India Business News, BMI#6INDIAN SCENARIO India is currently facing a chronic shortage of healthcare infrastructure, especially in rural areas and Tier II and Tier III cities, and it is expected that India will have a potential requirement of 1.75 million new beds by the end of 2025. The medical infrastructure market with an estimated growth rate of 15% is expected to reach US$ 200 billion by 2024. GOI INITIATIVES Ayushman Bharat aims to provide free health insurance of US$ 7,100 per family to nearly 40% of the population REVENUE SHARE OF INDIAN PHARMACEUTICAL SUB-SEGMENTS IN 2015 (%) (TOTAL PHARMA REVENUE, 2015: US$ 30 BILLION) +70% OTC market is expected to grow at a CAGR of 9% from 2016-26 to cross US$ 6.81 billion. Over 650 million people are expected to be covered by health insurance by 2020. GENERIC DRUGS 9% +21% OTC MEDICINES PATENTED DRUGS#7GIVING INDIA THE EDGE IN PHARMACEUTICALS COST LEADERSHIP DIVERSE RANGE OF PRODUCTS GLOBALLY RECOGNIZED CAPABILITIES LEADER IN DRUG APPLICATIONS LEADER IN MEDICAL TOURISM FDI CONDUCIVE PATENT REGIME Cost of production of pharmaceuticals in India is -60% lower than that of US and almost half of that of Europe. Over 60,000 generic brands across 60 therapeutic categories are manufactured in India. Out of all drug master filings from India, 49% are registered in the USA. Indian pharmaceutical industry accounts for the 2nd largest number of Abbreviated New Drug Applications (ANDAs). The value of medical tourism in India is expected to reach US$ 9 billion by 2020 Up to 100% FDI is allowed for manufacturing of medical devices/equipment. Patents for branded molecules with cumulative global sales of over US$251 billion are expected to expire between 2018 & 2024.#8INDIA'S PHARMACEUTICAL HUB MADHYA PRADESH SCENARIO F MAJOR EXPORT DESTINATION: US, UK, RUSSIA, NETHERLANDS, GERMANY. BRAZIL EMPLOYMENT GENERATED: MORE THAN 1,00,000 PEOPLE EMPLOYED IN PHARMA SECTOR EXPORT: US$ 2.8 BILLION FY 18-19 EDUCATION INFRASTRUCTURE - 110+ INSTITUTES PROVIDING DEGREE/ DIPLOMA IN PHARMA PHARMA CLUSTERS: INDORE, DEWAS. BHOPAL, MANDIDEEP MANUFACTURING FACILITIES: PITHAMPUR SEZ IS A MAJOR MANUFACTURING HUB CONDUCIVE#9CLIMATE CENTRALLY LOCATED WITH CATCHMENT AREA OF -50% OF INDIA'S POPULATION POLICY CATERING ALL NEEDS OF PHARMA & HEALTH CARE SECTOR 5 COMMERCIAL AIRPORTS AND 7 INLAND CONTAINER DEPOTS. 550 TRAINS TRANSIT THROUGH THE STATE, DAILY LO SKILLED WORKFORCE; UNINTERRUPTED WATER SUPPLY, ELECTRICITY INDUSTRIAL LAND BANK OF 1,20,000 ACRES OUT OF WHICH 48,000 ACRES IS DEVELOPED RECORDED AN IMPRESSIVE GROWTH IN CSDP, AVERAGE WAS OVER 9% DURING THE LAST DECADE#10MADHYA PRADESH SCENARIO SERVICING HEALTHCARE IN THE COUNTRY FOR HEALTH CARE SECTOR: SNAPSHOT (JULY, 2019) GOVERNMENT 13 MEDICAL & 1 DENTAL PRIVATE 7 MEDICAL & 13 DENTAL COLLEGES GOVERNMENT COLLEGES 1870 MBBS INTAKE (19-20) 63 BDS INTAKE (19-20) 2826 (20-21) PROPOSED INTAKE 9 (19-20) CURRENT INTAKE 300 (20-22) PROPOSED INTAKE DM/MCH SEATS (Super Specialty)#117860 (19-20) BED CAPACITY 16750 (21-22) PROPOSED BED CAPACITY SUPER SPECIALTY 1150 (19-20) MBBS INTAKE 1220 (19-20) BDS INTAKE PRIVATE COLLEGES TOTAL BEDS AVAILABLE ACROSS HOSPITALS 81,862 689 (19-20) CURRENT INTAKE 1338 (20-21) PROPOSED INTAKE PG SEATS#12MADHYA PRADESH SCENARIO OVERVIEW OF PHARMACEUTICAL SECTOR PHARMACEUTICALS SECTOR: SNAPSHOT (JULY, 2019) WHO-GMP COMPLIANT UNITS ‣ 8 BULK DRUGS ► 31 FORMULATIONS 4 LARGE VOLUME PARENTERAL DOING BUSINESS Online- Grant of license and GMP, GLP, Non-Convection. Marketstanding. Performance. Free sale certificate EXPORT 217 COUNTRIES PHARMA SECTOR EXPORT Online Test license, Addition of license in already existing drug manufacturing license CERTIFICATIONS WHO-GMP; USFDA; MHRA; NAFDAC, Nigeria: PPB Kenya; Liberian Ministry of health and regulatory affair Timelines under PSGA for major services. Online user manual and application tracking facility CERTIFICATIONS Sri Lanka Pharmacy Board; Ivory Coast; DR Congo; Ministry of Health Yemen#13MALANPUR PHARMACEUTICAL CLUSTER BHOPAL ▸ DEWAS ➤ MANDIDEEP ▸ INDORE MEDICAMENTS EXPORTED FROM MADHYA PRADESH (US$ MILLION) ITEM/COMMODITY 2012-13 2016-17 SHARE OF THE COMMODITY IN MP'S TOTAL EXPORTS IN % (2016-17) SHARE OF MP IN INDIA'S TOTAL EXPORTS OF THE COMMODITY IN % (2016-17) AVERAGE ANNUAL GROWTH RATE IN % (2012-13 TO 2016-17) Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic purposes 193.3 789.0 17.8 8.1 Medicaments containing antibiotics 134.3 171.4 3.9 17.8 Source: http://www.mpvdp.in/pharma.aspx: https://www.eximbankindia.in/Assets/Dynamic/PDF/Publication-Resources/Research Papers/Hindi/95file.pdf 48.2 6.9#14MADHYA PRADESH SCENARIO PRESENCE OF TOP PHARMA COMPANIES SUN PHARMA LUPIN TEUN Mylan G Glenmark PDPL Dabur A ARISTO ARISTO PHARMACEUTICALS PVT. LTD. LANXESS Energizing Chemistry Piramal Lipca A dose of life G SYMBIOTEC PHARMALAB (P) LIMITED torrent G3 ACG-Associated Capsules Cipla advanced enzymes Where ENZYME is Life PHARMA#15BOOSTER DOSE FOR PHARMA SECTOR GROWTH BY CENTRAL GOVERNMENT SCHEME FOR DEVELOPMENT OF HEALTHCARE INDUSTRY SCHEME COMPONENTS Assistance to Bulk Drug Industry for Common Facility Centre INCENTIVE TYPE Financial assistance for creation of common facilities in any upcoming Bulk Drug Park promoted by State Govern- ments/State Corporations PATTERN OF ASSISTANCE One time grant-in-aid to be released to a State Implementing Agency (SIA) set up for the purpose Total of US$ 28.19 million has been earmarked. Max. limit would be US$ 14.09 million/Bulk Drug Park CFC or 70% of the project cost of CFC whichever is less Assistance to Medical Device Industry for Common Facility Centre Financial assistance for creation of common facilities in any upcoming Medical Device Park promoted by State Govern- ments/State Corporations One time grant-in-aid to be released to a State Implementing Agency (SIA) set up for the purpose. The max. limit would be US$ 3.54 million/- Medical Device Park CFC or 70% of the project cost of CFC whichever is less. Pharmaceuticals Technology Upgradation Assistance Scheme Interest subvention assistance against sanctioned loan by any scheduled commercial bank/financial institution, both in Public and Private sector will be provided to 250 pharma SMEs of proven track record. A total of US$ 20.3 million has been earmarked for the scheme. The upper limit of interest subvention on loans for technology/ infrastructure upgradation shall be restricted to 6% per annum for a period of 3 years on reducing balance basis. The maximum loan eligible for this purpose will be US$ 0.56 million, availed by the concerned SME Assistance for Cluster Development Financial assistance for creation of common facilities in any pharma clusters including Bulk Drug, Medical Device, Ayurve- dic, Unani and Cosmetics Units. US$ 4.2 million was earmarked for the scheme including US$ 1.4 million which was allocated in 2017-18. Maximum limit for the grant in aid under this category would be US$ 2.8 million per cluster or 70% of the cost of project whichever is less Pharmaceutical Promotion Development Scheme Financial support for conducting seminars, conferences, exhibitions, mounting delegations to and from India for promotion of exports as well as investments, conducting studies/consultancies A total of US$ 0.8 million has been earmarked for the scheme. Sources: http://pharmaceuticals.gov.in/sites/default/files/Scheme%20for%20Development%20of%20Pharmaceutical%20Industry_2.pdf#16MADHYA PRADESH SCENARIO INJECTING CONFIDENCE IN PHARMA SECTOR INVESTMENT MADHYA PRADESH HEALTH SECTOR INVESTMENT PROMOTION POLICY Districts categorized into three categories BENEFITS UNDER THE POLICY: On setting up of - Multi-Speciality Hospital Grade-I Multi-Speciality Hospital Grade-II CAPITAL SUBSIDY FOR EXPANSION / UPGRADATION: Hospitals shall be given benefits/incentives for expansion of capacity or Up-gradation of diagnostic and treatment facilities # Super Speciality Hospital • Medical College 1. Land allotment: 20-40% concession on allotment of land 2. Capital Subsidy: 20-50% on total Investment Per seat assistance to Nursing College for starting Post Graduate Degree or Speciality area Nursing Courses ONLINE AND TIME BOUND CLEARANCES#17INDUSTRIAL PROMOTION POLICY India's only "tax delinked" investment assistance policy with focus on employment generation, priority block development and exports Transparent policy with online calculator for incentive calculation Green industrialization assistance for ETP/ CETP/Waste processing MP offers competitive land rates and power tariffs for industries For Infrastructure Development Assistance on private and undeveloped government land; 50% assistance subject to max of INR 1 crore each to be provided for developing power, water and road infrastructure Customized Incentives for companies with fixed capital investment of more than INR 100 crore#18MADHYA PRADESH SCENARIO INVESTMENT OPPORTUNITIES IN PHARMACEUTICAL INDUSTRY INVESTMENT OPPORTUNITIES > CONTRACT RESEARCH AND MANUFACTURING SERVICES INDUSTRY (CRAMS) > HIGH-END DRUGS > VACCINE DEVELOPMENT > PHARMA RETAIL CHAIN > POINT OF CARE TESTING (POCT) DIAGNOSTIC > FORMULATIONS > SURGICAL INSTRUMENTS > MEDICAL INFRASTRUCTURE > ORTHOPAEDIC AND PROSTHETIC APPLIANCES > BIOPHARMACEUTICALS > ACTIVE PHARMACEUTICAL INGREDIENTS (API) MEDICAL DEVICES AND DIAGNOSTIC KITS > CANCER DIAGNOSTICS > OPHTHALMIC INSTRUMENTS AND APPLIANCES > ORTHODONTIC EQUIPMENT AND DENTAL IMPLANTS > PHARMA MACHINERY > COSMETICS > MEDICAL IMAGING > BEAUTY PRODUCTS#19OFFICIAL CONTACTS PRINCIPAL SECRETARY Public Health & Family Welfare 4th Floor, Vallabh Bhawan-3, Bhopal, Madhya Pradesh Phone: 0755-2708808 Email: [email protected] Food and Drugs Administration Department Idgah Hills Bhopal 462030 Madhya Pradesh Phone: 0755-2665385 E-mail: [email protected] DISCLAIMER: Madhya Pradesh Industrial Development Corporation, Government of Madhya Pradesh (MPIDC) has made every attempt to ensure the accuracy and reliability of the information provided in this document. However, the information is provided "as is" without warranty of any kind. MPIDC periodically adds, changes, improves or updates the information in this document without any notice. For further clarification kindly reach out to [email protected].#20www.invest.mp.gov.in MP INDUSTRIAL DEVELOPMENT CORPORATION LIMITED 16-A, CEDMAP Bhawan, Arera Hills, Bhopal, Madhya Pradesh (INDIA) Phone: +91-755-2575618, 2571830 E-mail: [email protected] ORGANISED BY NATIONAL PARTNER KNOWLEDGE PARTNER MPIC Madhya Pradesh Industrial Development Corporation CII Confederation of Indian Industry EY Building a better working world